Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$333.00K$333.00K−82.0% vs Q1 2016 Net Income$49.29M$49.29MN/M vs Q1 2016 EPS Diluted$0.46$0.46N/M vs Q1 2016 Gross Profit$333,000−82.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$8,098,000N/M Free Cash Flowderived-$8,313,000N/M Margins · derivedGross margin100.0%±0.0 pt vs Q1 2016
Operating margin-3382.0%−2096.4 pt vs Q1 2016
Net margin14801.2%+15727.2 pt vs Q1 2016
ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end